Work

Overcoming immunosuppression to enhance a p53MVA vaccine

Year: 2014

Type: article

Abstract: A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immunomodulatory agents to deliver clinical benefit. Here, we outline our rationale for combining p53MVA with immunomodulatory chemotherapy in a forthcoming trial.

Source: OncoImmunology

DOI: 10.4161/21624011.2014.958949

Authors: Nicola Hardwick, Vincent Chung, Mihaela Cristea, Joshua DI Ellenhorn, Don J Diamond

Institutions: Beckman Research Institute, City Of Hope National Medical Center, Cedars-Sinai Medical Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913